U.K.-based digital health tech company Huma has received FDA 510(k) Class II clearance for its configurable disease-agnostic Software as a Medical Device platform, which includes the company's cardiovascular risk score algorithm.
The company, which received EU MDR Class IIb certification just three months ago, obtained FDA clearance in partnership with Health Canada through the FDA's joint eStar...
Digital health tech company Huma acquired clinical trial data specialist Alcedis, expanding the British company's capabilities in the digital clinical trial space.
Huma will create an advanced clinical trials division utilizing German-based Alcedis' platform that will offer digital health solutions spanning various stages of the development process, from early stage development to phase 4...
Huma acquires iPLATO healthcare
London-based patient engagement firm iPLATO Healthcare has been acquired by global healthtech firm Huma.
iPLATO’s software covers a network of 26.6 million patients across nearly 3,000 NHS primary care organisations and its myGP app is used by almost 2.4 million people in England.
The two companies will continue to operate independently but will combine their...
ATOS AND HUMA ENTER FIVE YEAR PARTNERSHIP
France-based information technology company, Atos and British digital healthcare innovator, Huma have announced a five-year strategic global partnership.
The collaboration aims to shift healthcare and clinical trials from hospital to home and will focus on Huma's modular platform which can power digital 'hospitals at home' up to a national scale. The...
Huma Therapeutics Ltd today announced the completion of its Series C funding round with financing of around $130 million.
Leaps by Bayer and Hitachi Ventures led the round, which also saw new strategic and financial investors become shareholders.
Samsung Next, Sony Innovation Fund by IGV, Unilever Ventures and HAT Technology & Innovation Fund by HAT, as well as individuals Nikesh Arora (...
The MRC Epidemiology Unit at the University of Cambridge has launched a research project using a remote monitoring platform from digital health company Huma in the Fenland Study.
Through Huma’s smartphone app, researchers will ask participants to provide detailed health data to provide insights into the detection and progression of COVID-19.
The study will measure antibodies to determine how many...
Digital health business Medopad has rebranded itself as Huma and acquired two AI and wearable tech companies, reinforcing its mission to play a pioneering role in discovering digital biomarkers, an emerging category of medicine described by founder and CEO Dan Vahdat as a “game-changer”.
Vahdat said the company’s focus on insights gathered by remote monitoring to help healthcare, life sciences...
